Ethnic and geographical distributions of CYP2C19 alleles in the populations of Southeast Asia

Advances in Experimental Medicine and Biology

Volumn 531, Issue , 2003, Pages 37-46

  Yusuf, Irawan ^a,b   Djojosubroto, Meta W ^a   Ikawati, Risma ^a   Lum, Koji ^c   Kaneko, Akira ^c   Marzuki, Sangkot ^a  

^a EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^b HASANUDDIN UNIVERSITY   (Indonesia)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BARBITURIC ACID DERIVATIVE; CHLORPROGUANIL; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2C19; DIAZEPAM; IMIPRAMINE; MEPHENYTOIN; OMEPRAZOLE; PROGUANIL; PROPANOL;

ALLELE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG METABOLISM; ERADICATION THERAPY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC DISTANCE; GENETIC DRIFT; GENETIC EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HELICOBACTER PYLORI; HUMAN; INDONESIA; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; NONHUMAN; PACIFIC ISLANDS; PEPTIC ULCER; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTHEAST ASIA;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 0041383004     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0059-9_3     Document Type: Conference Paper

References (38)

1. Adedoyin, A., Prakash, C., O'Shea, D., Blair, I.A., and Wilkinson, G.R., 1994, Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics 4: 27-38.
2. Andersson, T., Cederberg, C., Edvardsson, G., Heggelund, A., and Lundborg, P., 1990, Effect of omeprazole on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin. Pharmacol. Ther. 47: 79-85.
3. Andersson, T., Miners, J.O., Veronese, M.E., Tassaneeyakul, W., Meyer, U.A., and Birkett, D.J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36: 521-530.
4. Bertilsson, L., 1995, Geographical/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet.. 29: 192-209.
5. Bertilsson, L., Henthorn, T.K., Sanz, E., Tybring, G., Säwe, J., and Villén, T., 1989, Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin. Pharmacol. Ther. 45: 348-55.
6. Capelli, C., Wilson, J.F., Richards, M., Stumpf, M.P.H., Gratrix, F., Oppenheimer, S., et al., 2001, A predominantly indigenous paternal heritage for the Austronesian-speaking peoples of insular Southeast Asia and Oceanic. Am. J. Hum. Genet. 68: 432-443.
7. De Morais, S.M.F., Wilkilson, G.R., Blaisdell, J., Meyer, U.A., Nakamura, K., and Goldstein, J.A., 1994, The major genetic defect responsible for the polymorphisms of S-mephenytoin metabolism in humans. J. Biol. Chem. 269: 15419-15422.
8. Ferguson, R.J., De Morais, S.M., Benhamou, S., Bouchardy, C., Blaisdell, J., Ibeanu, G., Wilkinson, G.R., Sarich, T.C., Wright, J.M., Dayer, P., and Goldstein, J.A., 1998, A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp. Ther. 284: 356-361.
9. Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., et al., 1998, Effect of genetic differences in omeprazole metabolism on cure rate for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 29: 1027-1030.
10. Goldstein, J.A., and Blaisdell, J., 1996, Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 272: 210-217.
11. Goldstein, J.A., Ishizaki, T., Chiba, K., de Morais, S.M.F., Bell, D., Krahn, P.M., and Evans, D.A.P., 1997, Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7: 59-64.
12. Griese, E.U., Ilett, K.F., Kitteringham, N.R., Eichelbaum, M., Powell, H., Spargo, R.M., et al., 2001, Allele and genotype frequencies and polymorphic cytochromes P450 2D6, 2C19 and 2E1 in Aborigines from Western Australia. Pharmacogenetics 11: 69-76.
13. Herrlin, K., Massele, A.Y., Jande, M., Alm, C., Tybring, G., Abdi, Y.A., et al., 1998, Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther. 64: 391-401.
14. Ibeanu, G.C., Goldstein, J.A., Meyer, U., Benhamou, S., Bouchardy, C., Dayer, P., Ghanayem, B.I., and Blaisdell J., 1998, Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286: 1490-1495.
15. Ibeanu, G.C., Blaisdell, J., Ferguson, R.J., Ghanayem, B.I., Brosen, K., Benhamou, S., Bouchardy, C., Wilkinson, G.R., Dayer P, and Goldstein, J.A., 1999, A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther. 290: 635-640.
16. Kaneko, A., Lum, J.K., Yaviong, J., Takahashi, N., Ishizaki, T., Bertilsson, L., et al., 1999, High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific Islands. Pharmacogenetics 9: 581-590.
17. Kayser, M., Brauer, S., Weiss, G., Schiefenhovel, W., Underhill, P., and Stoneking, M., 2001, Independent histories of human Y chromosomes from Melanesia and Australia. Am. J. Hum. Genet. 68: 173-190.
18. Kimura, M., Ieiri, I., Mamiya, K., Urae, A., and Higuchi, S., 1998, Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug. Monit. 203: 243-247.
19. Kubota, T., Chiba, K., and Ishizaki, T., 1996, Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60: 661-666.
20. Lum, J.K., and Cann, R.L., 1998, mtDNA and language support a common origin of Micronesians and Polynesians in Island Southeast Asia. Am. J. Phys. Anthropol. 105: 109-119.
21. Lum, J.K., Cann, R.L., Martinson, J.J., and Jorde, L.B., 1998, Mitochondrial and nuclear genetic relationships among Pacific Island and Asian populations. Am. J. Hum. Genet. 63: 613-624.
22. Masimirembwa, C., Bertilsson, L., Johansson, I., Hasler, J.A., and Ingelman-Sundberg, M., 1995, Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther. 57: 656-661.
23. Nielsen, K.K., Flinois, J.P., Beaune, P., and Brosen, K., 1996, The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J. Pharmacol. Exp. Ther. 277: 1659-1664.
24. Persson, I., Aklillu, E., Rodrigues, F., Bertilsson, L., and Ingelman-Sundberg. M., 1996, S-Mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6: 521-526.
25. Poolsup, N., Li, W.P.A., and Knight, T.L., 2000, Pharmacogenetics and psychopharmacotherapy. J. Clin. Pharm. Ther. 25: 197-220.
26. Qin, X.P., Xie, H.G., Wang, W., He, N., Huang, S.L., Xu, Z.H., Ou-Yang, D.S., et al., 1999, Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin. Pharmacol. Ther. 66: 642-646.
27. Richards, M., Oppenheimer, S., and Sykes, B., 1998, mtDNA suggests Polynesian origins in eastern Indonesia. Am. J. Hum. Genet. 63: 1234-1236.
28. Richardson, T.H., Griffin, K.J., Jung, F., Raucy, J.L., and Johnson, E.F., 1997, Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch. Biochem. Biophys. 338: 157-164.
29. Roh, H.K., Dahl, M.L., Johansson, I., Ingelman-Sundberg, M., Cha, Y.N., and Bertilsson, L., 1996, Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6: 441-447.
30. Romkes, M., Faletto, M.B., Blaisdell, J.A., Raucy, J.L., and Goldstein, J.A., 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochem. 30: 3247-3255.
31. Sindrup, S.H., Brosen, K., Hansen, M.G.J., Aaes-Jorgensen, T., Overo, K.F., and Gram, L.F., 1993, Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther. Drug. Monit. 15: 11-17.
32. Taniwagara, Y., Aoyama, N., Kita, T., Shirakawa, K., Komada, F., Kasuga, M., and Okumura, K., 1999, CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 66: 528-534.
33. Thomson, R.J.M., Martinson, J.J., Norwich, J.T., Harding, R.M., Clegg, J.B., and Boettcher, B., 1996, An ancient common origin of Aboriginal Australians and New Guinea highlanders is supported by α-globin haplotypes analysis. Am. J. Hum. Genet. 58: 1017-1024.
34. Ventakakrishnan, K., Greenblatt, G.J., von Moltke, L.L., Schmider, J., Harmatz J.S., and Shader R.I., 1998, Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol. 38: 112-121.
35. Ward, S.A., Walle T., Walle, U.K., Wilkinson G.R., and Branch, R.A., 1989, Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin. Pharmacol. Ther. 45: 72-79.
36. Wright, J.D., Helsby, N.A., and Ward, S.A., 1995, The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br. J. Clin. Pharmacol. 39: 441-444.
37. Xiao, Z.S., Goldstein, J.A., Xie, H.G., Blaisdell, J., Wang, W., Jiang, C.H., et al., 1997, Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281: 604-619.
38. Yasumori, T., Li, Q.H., Yamazoe, Y., Ueda, M., Tsuzuki, T., and Kato, R., 1994, Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation. Pharmacogenetics 4: 323-331.